BioVie Inc. Form DEF 14A: Definitive proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-09-25: Form DEF 14A; Period of report 2025-09-25; Description DEF 14A; Document bivi-def14a.htm.
- 2025-06-02: Form DEF 14A; Period of report 2025-06-02; Description DEF 14A; Document bivi-def14a.htm.
- 2024-09-27: Form DEF 14A; Period of report 2024-09-27; Description PRE 14A; Document bivi-def14a.htm.
- 2024-06-17: Form DEF 14A; Period of report 2024-06-17; Description DEF 14A; Document bivi-def14.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2025-09-25 | DEF 14A | 2025-09-25 | DEF 14A | bivi-def14a.htm |
| 2025-06-02 | DEF 14A | 2025-06-02 | DEF 14A | bivi-def14a.htm |
| 2024-09-27 | DEF 14A | 2024-09-27 | PRE 14A | bivi-def14a.htm |
| 2024-06-17 | DEF 14A | 2024-06-17 | DEF 14A | bivi-def14.htm |
| 2023-09-29 | DEF 14A | 2023-09-29 | DEF 14A | bivi-def14a.htm |
| 2022-09-30 | DEF 14A | 2022-09-30 | DEF 14A | bivi-def14a.htm |
| 2021-09-14 | DEF 14A | 2021-09-13 | DEF 14A | bivi-def14a.htm |
| 2016-07-01 | DEF 14A | 2016-07-01 | DEF 14A | nnab-def14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |